Neoadjuvant chemotherapy associated with isotoxic high-dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduodenectomy for nonmetastatic pancreatic cancer.
Julie NavezChristelle BouchartLaura MansSoline DevosPatrizia LoiJean ClossetJean-Luc Van LaethemPublished in: Journal of surgical oncology (2023)
Incorporation of iHD-SBRT in the NAT sequence before PD for PC did not increase postoperative morbidity compared with upfront surgery. These results confirm the feasibility and safety of iHD-SBRT for the upcoming STEREOPAC trial.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- radiation therapy
- high dose
- patients undergoing
- rectal cancer
- sentinel lymph node
- lymph node
- minimally invasive
- squamous cell carcinoma
- radiation induced
- early stage
- coronary artery bypass
- low dose
- phase iii
- clinical trial
- study protocol
- phase ii
- randomized controlled trial
- coronary artery disease